Aberrant expression of cyclin E in low-risk node negative breast cancer
2008 (English)In: Acta Oncologica, ISSN 0284-186X, Vol. 47, no 8, 1539-1545 p.Article in journal (Refereed) Published
Background. Cyclin E is a cell cycle regulatory protein which occurs in G1, peaks in late G1 and is degraded in early S-phase. Cyclin E overexpression appears to be an independent prognostic factor for overall survival in breast cancer. Material and Methods. Nuclear cyclin A is a reliable marker for S-and G2-phases. Consequently, aberrant expression of cyclin E can be detected by simultaneous immunostainings for cyclin A and cyclin E. Studies have shown that aberrant cyclin E might provide additional prognostic information compared to that of cyclin E alone. This study aimed to investigate cyclin E and aberrant cyclin E expression in low-risk node negative breast cancer. We compared women that died from their breast cancer (n=17) with women free from relapse>8 years after initial diagnosis (n=24). All women had stage I, low risk breast cancer. The groups were matched regarding tumour size, receptor status, adjuvant chemotherapy and tumour differentiation. Tumour samples were analysed regarding expression of cyclin A, cyclin E and double-stained tumour cells using immunoflourescence staining and digital microscopy. Results. No differences were seen regarding expression of cyclin E or aberrant cyclin E in cases compared to controls. Discussion. We conclude that neither cyclin E nor aberrant cyclin E is a prognostic factor in low-risk node negative breast cancer patients.
Place, publisher, year, edition, pages
2008. Vol. 47, no 8, 1539-1545 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-97140DOI: 10.1080/02841860701856581ISI: 000260227700010PubMedID: 18607847OAI: oai:DiVA.org:uu-97140DiVA: diva2:171945